Harnessing preexisting influenza virus-specific immunity increases antibody responses against SARS-CoV-2.
Harrison DulinRamya S BarreDuo XuArrmund NealEdward VizcarraJerald ChavezArzu UluMyeon-Sik YangSiddiqur Rahman KhanKeidy WuangNikhil BhaktaChanvoraboth CheaEmma H WilsonLuis Martinez-SobridoRong HaiPublished in: Journal of virology (2024)
Increased globalization and changes in human interactions with wild animals has increased the likelihood of the emergence of novel viruses with pandemic potential. Vaccines can be effective in preventing severe disease caused by pandemic viruses. However, it takes time to develop protective immunity via prime-boost vaccination. More effective vaccine designs should quickly induce protective immunity. We propose leveraging preexisting immunity to a different pathogen to boost protection against emerging viruses. We targeted SARS-CoV-2 as a representative pandemic virus and generated a fusion protein vaccine that combines the nucleoprotein from influenza A virus and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Our vaccine design significantly increased the production of RBD-specific antibodies in mice that had previously been exposed to influenza virus, compared to those without previous exposure. This enhanced immunity reduced SARS-CoV-2 replication in mice. Our results offer a vaccine design that could be valuable in a future pandemic setting.